No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Yehiel Tal, Chief Executive Officer of CollPlant Is Elected to the BOD of ISBF

Editor: What To Know

  • Tal is a highly accomplished innovator in the field of 3D bioprinting and will bring a level of knowledge and passion that will greatly benefit our organization’s mission to foster scientific and technological advancement in the field of biofabrication that benefits humanity.
  • “I am honored to be elected to the Board of Directors of the ISBF, and to work with others who are shaping and advancing the field of biofabrication which holds great promise in development of in vitro 3D models, tissue engineering and regenerative therapies”.
  • Tal was appointed to the Board of Directors of ISBF in recognition of his deep involvement, experience and understanding of the 3D bioprinting industry.

Mr. Yehiel Tal, Chief Executive Officer of CollPlant, has been elected to the Board of Directors of the International Society for Biofabrication (ISBF) for a three-year term starting January 1st 2022.

Mr. Tal was appointed to the Board of Directors of ISBF in recognition of his deep involvement, experience and understanding of the 3D bioprinting industry. The ISBF is a scientific and professional Society, which promotes advances in Biofabrication research, development, education, training, and medical and clinical applications. The ISBF’s core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity.

“I am honored to be elected to the Board of Directors of the ISBF, and to work with others who are shaping and advancing the field of biofabrication which holds great promise in development of in vitro 3D models, tissue engineering and regenerative therapies” stated Mr. Tal.

“We are pleased to welcome Mr. Tal to ISBF’s Board of Directors,” stated Prof.  James J. Yoo, ISBF President, ”  Mr. Tal is a highly accomplished innovator in the field of 3D bioprinting and will bring a level of knowledge and passion that will greatly benefit our organization’s mission to foster scientific and technological advancement in the field of biofabrication that benefits humanity.”

The International Society for Biofabrication (ISBF) is a scientific and professional Society, which promotes advances in Biofabrication research, development, education, training, and medical and clinical applications. ISBF represents the international Biofabrication community and operate as a non-profit organization. ISBF’s core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity. ISBF promote the interaction between the different disciplines of the field of Biofabrication, as well as between basic research and applied practice; and cooperate with other scientific organizations and communities.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy